Skip to main content
Timothy Call, MD, Oncology, Rochester, MN

TimothyGeorgeCallMD

Oncology Rochester, MN

Associate Professor, Internal Medicine, Mayo Medical School

Dr. Call is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Call's full profile

Already have an account?

  • Office

    200 1st St Sw
    Rochester, MN 55905
    Phone+1 507-284-2511

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1989 - 1993
  • Gundersen Lutheran Medical Foundation
    Gundersen Lutheran Medical FoundationResidency, Internal Medicine, 1980 - 1983
  • University of Wisconsin School of Medicine & Public Health
    University of Wisconsin School of Medicine & Public HealthClass of 1980

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 1990 - 2025
  • WI State Medical License
    WI State Medical License 1981 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre  
    Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology

Abstracts/Posters

  • A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
    Timothy G. Call, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...
    Timothy G. Call, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
    Timothy G. Call, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Newer CLL Agents Require Specific Management Techniques
    Newer CLL Agents Require Specific Management TechniquesJune 27th, 2017

Professional Memberships